{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:45:38Z","timestamp":1791974738507,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.leukres.2026.108341","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:17:53Z","timestamp":1791818273000},"page":"108341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["NGS-based retrospective profiling of BCR::ABL1 kinase domain mutations in chronic myeloid leukemia: Findings from the largest South Asian cohort"],"prefix":"10.1016","volume":"171","author":[{"given":"Jagmohan Singh","family":"Bali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritika","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi Pannayanapalya","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakthivel","family":"Murugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108341_bib1","series-title":"Classification of Tumours: Haematolymphoid Tumours","author":"World Health Organization (WHO)","year":"2022"},{"key":"10.1016\/j.leukres.2026.108341_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cytogfr.2025.05.001","article-title":"BCR-ABL: the molecular mastermind behind chronic myeloid leukemia","volume":"83","author":"Shammas","year":"2025","journal-title":"Cytokine Growth Factor. Rev."},{"issue":"4","key":"10.1016\/j.leukres.2026.108341_bib3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.leukres.2026.108341_bib4","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.3390\/ijms20246141","article-title":"Mechanisms of disease progression and resistance to ibitor therapy in chronic myeloid leukemia: an update","volume":"20","author":"Bavaro","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.leukres.2026.108341_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00277-015-2539-0","article-title":"Detection of BCR::ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing","volume":"95","author":"Szankasi","year":"2016","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108341_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bjh.17301","article-title":"Next-generation sequencing improves BCR::ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"193","author":"Soverini","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"16","key":"10.1016\/j.leukres.2026.108341_bib7","doi-asserted-by":"crossref","first-page":"21982","DOI":"10.18632\/oncotarget.8010","article-title":"Next-generation sequencing for sensitive detection of BCR::ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients","volume":"7","author":"Soverini","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.leukres.2026.108341_bib8","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.3390\/jcm9123865","article-title":"Molecular testing in CML between old and new methods: are we at a turning point?","volume":"9","author":"Soverini","year":"2020","journal-title":"J. Clin. Med."},{"issue":"20","key":"10.1016\/j.leukres.2026.108341_bib9","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association. world medical association declaration of helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.leukres.2026.108341_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, american society of clinical oncology, and college of american pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J. Mol. Diagn."},{"issue":"4","key":"10.1016\/j.leukres.2026.108341_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/gtmb.2010.0036","article-title":"Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations","volume":"14","author":"Flanagan","year":"2010","journal-title":"Genet. Test. Mol. Biomark."},{"issue":"1","key":"10.1016\/j.leukres.2026.108341_bib12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/pro.3942","article-title":"DynaMut2: assessing changes in stability and flexibility upon single and multiple point missense mutations","volume":"30","author":"Rodrigues","year":"2021","journal-title":"Protein Sci."},{"issue":"1","key":"10.1016\/j.leukres.2026.108341_bib13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2019-126767","article-title":"Detection of actionable BCR::ABL1 kinase domain mutations: impact of NGS over Sanger sequencing","volume":"134","author":"Soverini","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108341_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13104-024-06772-1","article-title":"Mutation analysis of BCR::ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study","volume":"17","author":"Seman","year":"2024","journal-title":"BMC Res. Notes"},{"issue":"6","key":"10.1016\/j.leukres.2026.108341_bib15","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3324\/haematol.2010.039321","article-title":"Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy","volume":"96","author":"Quint\u00e1s-Cardama","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.leukres.2026.108341_bib16","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1002\/cam4.2946","article-title":"Next-generation sequencing for BCR::ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper","volume":"9","author":"Soverini","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.leukres.2026.108341_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2023.1611518","article-title":"Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia","volume":"29","author":"Hasanova","year":"2023","journal-title":"Pathol. Oncol. Res."},{"issue":"5531","key":"10.1016\/j.leukres.2026.108341_bib18","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.leukres.2026.108341_bib19","first-page":"1735","article-title":"Structural basis for TKI resistance via T315I mutation","volume":"26","author":"Redaelli","year":"2012","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.leukres.2026.108341_bib20","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2026.108341_bib21","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR::ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108341_bib22","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"H\u00f6glund","year":"2015","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108341_bib23","doi-asserted-by":"crossref","first-page":"10468","DOI":"10.18632\/aging.202809","article-title":"Global, regional, and national burdens of leukemia from 1990 to 2017: a systematic analysis of the global burden of disease 2017 study","volume":"13","author":"Lin","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1016\/j.leukres.2026.108341_bib24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes in ENESTnd and DASISION extension studies","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"32","key":"10.1016\/j.leukres.2026.108341_bib25","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1200\/JCO.2011.35.0934","article-title":"Sensitive detection of BCR::ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy","volume":"29","author":"Parker","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.leukres.2026.108341_bib26","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood.V122.21.3824.3824","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108341_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","article-title":"Next-generation sequencing for BCR::ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper","volume":"12","author":"Soverini","year":"2019","journal-title":"J. Hematol. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:55:11Z","timestamp":1791971711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":27,"alternative-id":["S0145212626001852"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108341","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NGS-based retrospective profiling of BCR::ABL1 kinase domain mutations in chronic myeloid leukemia: Findings from the largest South Asian cohort","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108341"}}